company background image

Shionogi TSE:4507 Stock Report

Last Price


Market Cap







06 Aug, 2022


Company Financials +
4507 fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance2/6
Financial Health6/6

4507 Stock Overview

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.


Trading at 48.1% below our estimate of its fair value

Earnings are forecast to grow 1.67% per year

Pays a reliable dividend of 1.78%

Risk Analysis

No risks detected for 4507 from our risk checks.

Shionogi Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shionogi
Historical stock prices
Current Share PriceJP¥6,755.00
52 Week HighJP¥8,439.00
52 Week LowJP¥6,063.00
1 Month Change-3.64%
3 Month Change-7.87%
1 Year Change11.88%
3 Year Change17.97%
5 Year Change16.65%
Change since IPO616.33%

Recent News & Updates

Shareholder Returns

4507JP PharmaceuticalsJP Market

Return vs Industry: 4507 exceeded the JP Pharmaceuticals industry which returned 6% over the past year.

Return vs Market: 4507 exceeded the JP Market which returned -0.1% over the past year.

Price Volatility

Is 4507's price volatile compared to industry and market?
4507 volatility
4507 Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement4.1%
Market Average Movement3.9%
10% most volatile stocks in JP Market8.1%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4507 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 4507's weekly volatility (5%) has been stable over the past year.

About the Company

18785,693Isao Teshirogi

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity.

Shionogi Fundamentals Summary

How do Shionogi's earnings and revenue compare to its market cap?
4507 fundamental statistics
Market CapJP¥2.03t
Earnings (TTM)JP¥116.67b
Revenue (TTM)JP¥338.01b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4507 income statement (TTM)
Cost of RevenueJP¥56.03b
Gross ProfitJP¥281.98b
Other ExpensesJP¥165.31b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)387.49
Gross Margin83.42%
Net Profit Margin34.52%
Debt/Equity Ratio0%

How did 4507 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio

Does 4507 pay a reliable dividends?

See 4507 dividend history and benchmarks
When do you need to buy 4507 by to receive an upcoming dividend?
Shionogi dividend dates
Ex Dividend DateSep 29 2022
Dividend Pay DateDec 01 2022
Days until Ex dividend53 days
Days until Dividend pay date116 days

Does 4507 pay a reliable dividends?

See 4507 dividend history and benchmarks
We’ve recently updated our valuation analysis.


Is 4507 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4507?

Other financial metrics that can be useful for relative valuation.

4507 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.5x
Enterprise Value/EBITDA15.4x
PEG Ratio10.4x

Price to Earnings Ratio vs Peers

How does 4507's PE Ratio compare to its peers?

4507 PE Ratio vs Peers
The above table shows the PE ratio for 4507 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average26.6x
4151 Kyowa Kirin
4523 Eisai
4528 Ono Pharmaceutical
4578 Otsuka Holdings
4507 Shionogi

Price-To-Earnings vs Peers: 4507 is good value based on its Price-To-Earnings Ratio (17.4x) compared to the peer average (26.6x).

Price to Earnings Ratio vs Industry

How does 4507's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 4507 is good value based on its Price-To-Earnings Ratio (17.4x) compared to the JP Pharmaceuticals industry average (17.4x)

Price to Earnings Ratio vs Fair Ratio

What is 4507's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4507 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.4x
Fair PE Ratio23.7x

Price-To-Earnings vs Fair Ratio: 4507 is good value based on its Price-To-Earnings Ratio (17.4x) compared to the estimated Fair Price-To-Earnings Ratio (23.7x).

Share Price vs Fair Value

What is the Fair Price of 4507 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4507 (¥6755) is trading below our estimate of fair value (¥13017.47)

Significantly Below Fair Value: 4507 is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Future Growth

How is Shionogi forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score


Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4507's forecast earnings growth (1.7% per year) is above the savings rate (0.04%).

Earnings vs Market: 4507's earnings (1.7% per year) are forecast to grow slower than the JP market (8.6% per year).

High Growth Earnings: 4507's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4507's revenue (2% per year) is forecast to grow slower than the JP market (4.4% per year).

High Growth Revenue: 4507's revenue (2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4507's Return on Equity is forecast to be low in 3 years time (12.3%).

Discover growth companies

Past Performance

How has Shionogi performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4507 has high quality earnings.

Growing Profit Margin: 4507's current net profit margins (34.5%) are lower than last year (41.6%).

Past Earnings Growth Analysis

Earnings Trend: 4507's earnings have grown by 1.5% per year over the past 5 years.

Accelerating Growth: 4507's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4507 had negative earnings growth (-4.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.2%).

Return on Equity

High ROE: 4507's Return on Equity (11.2%) is considered low.

Discover strong past performing companies

Financial Health

How is Shionogi's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 4507's short term assets (¥683.9B) exceed its short term liabilities (¥129.8B).

Long Term Liabilities: 4507's short term assets (¥683.9B) exceed its long term liabilities (¥34.6B).

Debt to Equity History and Analysis

Debt Level: 4507 is debt free.

Reducing Debt: 4507 has no debt compared to 5 years ago when its debt to equity ratio was 5.6%.

Debt Coverage: 4507 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4507 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Shionogi current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 5/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Upcoming Dividend Payment

TodayAug 06 2022Ex Dividend DateSep 29 2022Dividend Pay DateDec 01 202263 days from Ex DividendBuy in the next 53 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 4507's dividend (1.78%) is higher than the bottom 25% of dividend payers in the JP market (1.63%).

High Dividend: 4507's dividend (1.78%) is low compared to the top 25% of dividend payers in the JP market (3.62%).

Stability and Growth of Payments

Stable Dividend: 4507's dividends per share have been stable in the past 10 years.

Growing Dividend: 4507's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (29.7%), 4507's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (50.1%), 4507's dividend payments are covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Isao Teshirogi (63 yo)





Dr. Isao Teshirogi, Ph D., serves as Chairman at Shionogi & Co., Ltd. since 2022.Dr. Teshirogi serves as Independent Director for AGC Inc. since March 2022. He has been the President and Chief Executive O...

CEO Compensation Analysis

Compensation vs Market: Isao's total compensation ($USD1.78M) is about average for companies of similar size in the JP market ($USD1.53M).

Compensation vs Earnings: Isao's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

Leadership Team

Experienced Management: 4507's management team is considered experienced (4.8 years average tenure).

Board Members

Experienced Board: 4507's board of directors are considered experienced (5.2 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Shionogi & Co., Ltd.'s employee growth, exchange listings and data sources

Key Information

  • Name: Shionogi & Co., Ltd.
  • Ticker: 4507
  • Exchange: TSE
  • Founded: 1878
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: JP¥2.034t
  • Shares outstanding: 301.09m
  • Website:

Number of Employees


  • Shionogi & Co., Ltd.
  • 1-8, Doshomachi 3-chome
  • Chuo-ku
  • Osaka
  • 541-0045
  • Japan


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/06 00:00
End of Day Share Price2022/08/05 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.